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Information on the immunopathobiology of coronavirus disease 2019 (COVID-19) is rapidly
increasing; however, there remains a need to identify immune features predictive of fatal
outcome. This large-scale study characterized immune responses to severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) infection using multidimensional flow cytometry, with
the aim of identifying high-risk immune biomarkers. Holistic and unbiased analyses of 17
immune cell-types were conducted on 1,075 peripheral blood samples obtained from 868
COVID-19 patients and on samples from 24 patients presenting with non-SARS-CoV-2
infections and 36 healthy donors. Immune profiles of COVID-19 patients were significantly
different from those of age-matched healthy donors but generally similar to those of patients
with non-SARS-CoV-2 infections. Unsupervised clustering analysis revealed three
immunotypes during SARS-CoV-2 infection; immunotype 1 (14% of patients) was
characterized by significantly lower percentages of all immune cell-types except neutrophils
and circulating plasma cells, and was significantly associated with severe disease. Reduced
B-cell percentage was most strongly associated with risk of death. On multivariate analysis
incorporating age and comorbidities, B-cell and non-classical monocyte percentages were
independent prognostic factors for survival in training (n=513) and validation (n=355) cohorts.
Therefore, reduced percentages of B-cells and non-classical monocytes are high-risk
immune biomarkers for risk-stratification of COVID-19 patients.
Keywords: COVID-19, SARS-CoV-2, flow cytometry, lymphopenia, outcome, survival, biomarkersorg May 2021 | Volume 12 | Article 6590181
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Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
infections have resulted in 132 million confirmed cases of
coronavirus disease 2019 (COVID-19), including almost 3
million deaths, worldwide (https://covid19.who.int/). Age, pre-
existing medical conditions, male gender, and immune system
hyperactivation are associated with a higher risk of severe disease
(1–5). Patients with severe COVID-19 have abnormally high
levels of pro-inflammatory cytokines, leukocytosis, and
lymphopenia, although it is unknown whether these immune
perturbations are associated with specific comorbidities or are
independent drivers of COVID-19 severity (1). Furthermore,
general inflammation increases with age, and this could either
inhibit immunity to infections or initiate an inflammatory
cascade, amplifying the excessive inflammation that occurs in
response to pathogens (6). Thus, dissecting dysfunctional
immune signatures in the context of age and comorbidities
could be of paramount importance for optimal risk-
stratification of COVID-19 patients and the design of tailored
treatment strategies (7).
An increasing number of studies suggest that reduced innate
antiviral defenses, coupled with heightened inflammation, are
defining features of severe COVID-19 (8, 9). These observations
using single-cell RNA-sequencing or mass cytometry have come
from deep immune profiling of either nasopharyngeal, bronchial,
and post-mortem lung samples or peripheral blood (PB) (10)
from relatively small numbers of patients (8, 9, 11–18). Larger-
scale analyses using flow cytometry have shown COVID-19
patients to have reduced numbers of CD4 and CD8 T cells,
especially patients aged ≥60 years and/or those requiring
intensive care unit (ICU) admission (1, 19–23). The importance
of myeloid cells in severe COVID-19 has also been determined
(16, 18, 24). Namely, an excessive inflammatory response to
SARS-CoV-2 is a major cause of disease severity and death, and
is associated with a profound lymphopenia, neutrophil activation,
immune cell infiltration in several tissues, altered monocyte
activation, and high levels of circulating cytokines (25, 26).
Conversely, a loss of function in myeloid cells has also been
described to mirror an immune pathological status progressing
from immune paralysis to “immune silence”, which is associated
with higher susceptibility to fatal COVID-19 (26). These data
highlight the relevance of immune-monitoring for identifying
patients who may become critically ill. However, they fall short of
providing a comprehensive immunophenotypic atlas of COVID-
19, probably due to limited data from large patient cohorts on the
relative distribution of innate and adaptive immune cell-types,
including pro-inflammatory granulocytic cells, in whole PB
samples (10, 21–23, 27–29). Furthermore, a considerable
number of immune features associated with SARS-CoV-2
infection are not being routinely used for risk-stratification of
COVID-19 patients.
We hypothesized that a comprehensive analysis of immune
responses in a large cohort of patients would accelerate our
understanding of the immunopathobiology of COVID-19 and
potentially identify immune biomarkers for risk-stratification that
could be complementary to other well-known prognostic factors.Frontiers in Immunology | www.frontiersin.org 2MATERIAL AND METHODS
Patients and Subjects
Between March and May 2020, 537 consecutive patients
aged ≥18 years with clinical symptoms suggestive of COVID-
19 were admitted to the Clinica Universidad de Navarra. Of
these, 513 had a positive SARS-CoV-2 PCR test and/or presence
of SARS-CoV-2-specific antibodies, and represent the
exploratory series of COVID-19 patients investigated in this
study. The remaining 24 patients had a negative SARS-CoV-2
PCR test and/or no SARS-CoV-2-specific antibodies, and were
diagnosed instead with pneumonia (n=16), respiratory tract
infections (n=4), soft tissue infection (n=1), infectious
mononucleosis (n=1), urinary tract infection (n=1), and sepsis
after infection (n=1). Between June 2020 and February 2021,
another 355 COVID-19 patients aged ≥18 years were admitted
to the Clinica Universidad de Navarra and represent the
validation series.
Patients with COVID-19 were staged according to the clinical
risk score of Liang et al. (30). General ward admission criteria
included characteristic radiographic findings and/or shortness of
breath defined as tachypnea and/or low oxygen pulse in absence of
alternative diagnosis. Criteria for ICU admission included low
oxygen pulse despite supplementary oxygen with non-rebreather
mask, sepsis per Sequential Organ Failure Assessment (SOFA)
criteria and/or requiring mechanical ventilation, shock requiring
vasopressor drugs, and unexplained confusion. All patients received
standard supportive care, including low-molecular-weight heparin,
statins, and supplementary oxygen on demand. Patients with severe
COVID-19, with oxygen saturation of ≤90%, additionally received
corticosteroids, and critically ill patients received further tocilizumab.
Antiviral therapy with hydroxychloroquine/azythromycin or
ritonavir/lopinavir was administered depending on disease severity.
This study also included 36 healthy donors (HD) to provide
an age-matched reference cohort for comparison of immune
profiles. HDs had no prior diagnosis of or recent symptoms
consistent with COVID-19, and had a negative SARS-CoV-2
PCR test at the time of sample collection.
Study Design
PB samples were obtained for immune profiling from the 868
COVID-19 patients and the 24 patients with other infections at
the time of admission. Additionally, subsequent longitudinal
samples were collected over time (n=207) from 167 COVID-19
patients (Supplemental Table 1). The aim was to determine
whether COVID-19 outcome was associated solely with immune
status at presentation or if different immune response trajectories
over time were associated with different outcomes. Relative
changes in immune cell-type levels from presentation through
subsequent PB sample collection time points were evaluated
according to COVID-19 outcome. PB samples were also
collected from the 36 HDs. Identical immunophenotyping was
performed using multidimensional flow cytometry (MFC) on all
1,135 samples to characterize immune profiles in COVID-19
patients and to compare these with immune profiles in response
to other pathogens and HDs. Moreover, a deep analysis of
myeloid and T and B cells was carried out by transcriptomicsMay 2021 | Volume 12 | Article 659018
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14 COVID-19 patients and 4 HDs.
The 36 HDs were segmented into four age groups to provide
age-matched reference immune profiles for young adults (aged
18–30 years, n=8), middle-age adults (aged 31–55 years, n=8),
elderly but more likely fit subjects (aged 56–70 years, n=11), and
elderly and more likely unfit subjects (aged >70 years, n=9).
COVID-19 patients were segmented into the same four age
groups and immune profiles compared versus the respective
HDs to determine variations in cell-type proportions.
The Clinica Universidad de Navarra Ethics Committee
approved the protocol and informed consent forms, which
patients were required to sign prior to enrollment. The study
was conducted per the ethical principles of the Declaration
of Helsinki.
MFC Immunophenotyping and Automated
Clustering of PB Immune Cells
EDTA anti-coagulated PB samples were stained with the 8-color
combination of the monoclonal antibodies CD3-V450, CD45-
V500, CD20-FITC, CD16-PE, CD4-PerCPCy5.5, CD19-PECy7,
CD56-APC, and CD8-APCH7 (Supplemental Table 2), lysed
for 30 min, and measured directly – without centrifugation and
washing steps to minimize risk of infection – in a FACSCanto II
flow cytometer (Beckton Dickinson Biosciences [BD], San Jose, CA,
USA) using FACSDiva 6.1 software (BD). In a subset of 14 COVID-
19 patients and 4 HDs, PB T and B cells were characterized using
EuroFlow panels for primary immunodeficiencies (31).
Data were analyzed using FlowCT, a semi-automated workflow
we developed for deconvolution of immunophenotypic data and
objective reporting on large datasets (Figures 1A, B) (32). Briefly,
this four-step approach involves: 1) reading data; 2) building a self-
organizing map using FlowSOM (version 1.14.1) (33) for clustering
and dimensionality reduction; 3) building a minimum spanning
tree to connect nodes according to their similarity; and
4) computing an automated meta-clustering by grouping similar
nodes. The meta-clustering step is critical for the definition of cell
populations; in this phase, groups of similar nodes are “fused” per
specific algorithms [ConsensusClusterPlus (34) (version 1.46.0)
R package] to obtain more consistent populations. FlowCT
identified 17 immune cell-types for this analysis: basophils,
eosinophils, neutrophils, classical and non-classical monocytes,
immunoregulatory (CD16-CD56hi) and cytotoxic (CD16+CD56lo)
NK cells, eight T cell subsets (double-negative, double-positive,
CD4+CD56-, CD4+CD56+, CD8loCD56-, CD8-/loCD56+,
CD8hiCD56-, CD8hiCD56+), B cells, and circulating plasma cells
(PCs) (Figure 1B, Supplemental Figure 1, Supplemental Table 3).
Fluorescence-Activated Cell Sorting
Various myeloid subsets and antigen-presenting cells from 11
COVID-19 patients and 4 HDs were stained with the
combination HLADR-PacB, CD45-OC515, CD16-FITC,
CD203c-PE, CD33-PerCPCy5.5, CD123-APC, CD14-APCH7
(Supplemental Table 2), and isolated in a MoFlo Astrios EQ
sorter (Beckman Coulter, Brea, CA, USA). Based on its six-way
sorting, basophils, myeloid and plasmacytoid dendritic cells
(DC), classical and non-classical monocytes and neutrophilsFrontiers in Immunology | www.frontiersin.org 3were simultaneously isolated from PB samples of 11 COVID-
19 patients and 4 HDs with a purity greater than 95%. The gating
strategy and mRNA expression of key markers that define each
cell type are shown in Supplemental Figure 2. All cell types were
successfully isolated in all cases except for plasmacytoid DCs and




RNA-seq was performed using a protocol adapted from
massively parallel single-cell RNA-sequencing (35), which
enabled preparing libraries with as few cells as starting
material. Briefly, we barcoded RNA from each sample in a
retrotranscription (RT) reaction with AffinityScript Multiple
Temperature Reverse Transcriptase (Agilent, Santa Clara, CA,
USA) and different RT primers. After qPCR, cDNA with similar
Ct values were pooled together. cDNA was purified with
SPRIselect 1.2X (Beckman Coulter, Brea, CA, USA) and in
vitro-transcribed with the T7 polymerase (New England
Biolabs –NEB-, Ipswich, MA, USA) using the T7 promoter as
template, introduced in the previous RT reaction. Samples were
incubated for 16 hours at 37°C. RNA molecules were fragmented
with 2 µL of 10X Zn2+ fragmentation buffer (Ambion™,
ThermoFisher, Waltham, MA, USA) for 1 min at 70°C and
purified with SPRIselect 2X. Afterwards, a ssRNA adaptor
(Illumina, San Diego, CA, USA) was ligated to the 3’end of the
RNA fragments in the presence of DMSO, 100 mM ATP, 50%
PEG and T4 RNA ligase I (NEB, Ipswich, MA, USA) for 2 hours
at 22°C. A second RT reaction was performed with AffinityScript
Multiple Temperature Reverse Transcriptase and resulting
cDNA was purified with SPRIselect 1.5X. Finally, cDNA was
amplified with 12.5 µL Kappa Hifi ready mix + 1 µL of primer
mix at 25 µM per sample and purified with SPRIselect 0.7X.
Qubit, TapeStation and qPCR analyses were done as quality
controls and the final library products at 4 nM were sequenced in
a NextSeq 500 (Illumina, San Diego, CA, USA).
Raw sequencing data were demultiplexed through bcl2fastq
software (version 2.20.0, Illumina, San Diego, CA, USA) and
aligned to the GRCh38 human genome using STAR aligner
(version 2.7.3a) (36). Matrix with gene counts were generated
with quant3p [a wrapper based on HTSeq dynamics (37)].
Differential gene expression across all comparisons (COVID-19
patients vs HDs, and patients with favorable vs fatal outcome) of
sorted immune populations was analyzed with Deseq2 R package
(version 1.28.1) (38). Functional enrichment analysis was
performed through ClusterProfiler R package (39) considering
an adjusted P < 0.05.
Statistical Analysis
Immune profiles were compared between groups of patients/
subjects using proportions or absolute levels of immune cell-
types. The Kruskal–Wallis and Mann–Whitney tests were used
to estimate the statistical significance observed between groups,
and the c2 test was used to test distributions between
immunotypes resulting from unsupervised clustering. Multiple
comparisons were corrected by the Holm method.May 2021 | Volume 12 | Article 659018
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factors associated with overall survival (OS), a double Cox
regression approach was performed: first, a univariable model
was used to evaluate the prognostic value of each individual
immune cell-type, as well as other clinical features, and then a
multivariable regression was conducted using variables with
P<0.05 and hazard ratio (HR)>5 on univariable analysis. Cutoff
values for prognostic associations of individual immune cell-type
percentages with COVID-19 outcome (alive vs dead) were thoseFrontiers in Immunology | www.frontiersin.org 4providing maximum sensitivity and specificity on receiver
operating characteristic (ROC) curves. Survival probabilities
were estimated using the Kaplan–Meier method; between-group
differences were tested for statistical significance with two-sided
log-rank tests, and HRs, plus two-sided 95% confidence intervals
(CIs), were estimated using Cox regression models. Survival time
was measured from initial PB sampling at presentation.
All statistical analyses were performed using the GraphPad Prism




FIGURE 1 | Immune profiling of patients with COVID-19, patients with non-SARS-CoV-2 infections, and healthy donors (HDs). (A) Immune profiling was performed
using multidimensional flow cytometry in a training series of 513 patients with COVID-19, 24 patients with other infections, and 36 HDs. (B) Schematic representation
of the 17 immune cell-types systematically identified through unbiased and semi-automated analysis in peripheral blood (PB) samples from all subjects included in
the study (n=573). (C) Immune cell-type percentages in PB samples of HDs by age group (18–30 years, n=8; 31–55 years, n=8; 56–70 years, n=11; >70 years, n=9)
for cell-types with significantly different levels across age groups. *P <0.05; **P <0.01; ***P <0.001 in all panels. Statistical significance was evaluated using the
Kruskal–Wallis test, with multiple testing corrected using the Holm method. (D) Immune response in patients with COVID-19 (n=513) and in patients with other
infections (n=24), illustrated as the variations in the median percentages of each cell-type versus the median values in age-group-matched HDs (n=36, blue line).
Orange asterisks indicate significant differences between patients with COVID-19 and HDs, and green asterisks indicate significant differences between patients with
other infections and HDs. Hash symbols (#) indicate significant differences between patients with COVID-19 and patients with other infections (P <0.05). Statistical
significance was evaluated using Mann-Whitney test.May 2021 | Volume 12 | Article 659018
Martı́ n-Sá nchez et al. Immune Biomarkers for COVID-19 SeverityIBM, Chicago, IL, USA), and R (versions 3.5.1 and 4.0.0 for MFC
and RNA-seq studies, respectively). P values of <0.05 were
considered statistically significant.RESULTS
Patient Characteristics and Disposition
Among the 513 COVID-19 patients of the exploratory cohort,
median age at presentation was 60 years (range, 19–94) and 49%/
51% were male/female (Table 1). The most frequent
comorbidities were hypertension (35%), diabetes (11%),
cardiovascular disease (11%), and hypercholesterolemia (10%).
Overall, 395 (77%) patients were hospitalized, including 32 (6%)
who required ICU admission, and 23 (4%) died from COVID-19
(Table 1). At data cutoff, median follow-up in COVID-19
patients was 59 days.
Immune Profiling of HDs
HDs aged >70 years had a significantly higher percentage
of neutrophils and significantly lower percentages of
immunoregulatory NK cells versus younger age groups (Figure
1C). Percentages of double-negative, CD8loCD56-, and
CD8hiCD56- T cells progressively reduced with increasing age.
Percentages of other immune cell-types by age group are shown
in Supplemental Figure 3; there was a non-significant trend
(P=0.11) towards a lower B-cell percentage with increasing age.
Immune Response in COVID-19 Patients
At presentation, COVID-19 patients (n=513) showed significant
alterations in the proportions of 11 of the 17 immune cell-types
investigated, compared to age-matched HDs (Figure 1D). The
median percentage of neutrophils was 8% higher (P=0.014),
whereas there were significant reductions in the median
percentages of basophils, eosinophils, and non-classical
monocytes. There were also significant reductions in theFrontiers in Immunology | www.frontiersin.org 5median percentages of four T cell subsets (double-negative,
CD8loCD56-, CD8–/loCD56+, CD8hiCD56-) but a significant
increase in CD4+CD56+ T cells; similarly, there was a
significant increase in the percentage of mature circulating PCs
and a significant reduction of B cells. The immune profile of the
COVID-19 patients was generally similar to that of the 24 patients
with non-SARS-CoV-2 infections in terms of differences versus
age-matched HDs, except for significantly lower reductions in the
percentages of basophils and B cells (Figure 1D). Collectively,
these results suggest that most COVID-19 patients have an
immune profile in PB consistent with an active immune response.
Activation and Differentiation of Innate
and Adaptive Immune Cells After
SARS-CoV-2 Infection
Weperformed RNA-seq in various myeloid andDC subsets isolated
by FACS, to further investigate immune cell activation in COVID-
19 patients (n=11) vs. HDs (n=4). There was a progressive
increment of differentially expressed genes (DEGs) from myeloid
DC into basophils, plasmacytoid DC, classical monocytes,
neutrophils and non-classical monocytes (Figure 2A). Most DEGs
were over-expressed, with overlapping functional enrichment across
different cell types related to antimicrobial humoral response,
inflammatory response regulation and neutrophil activation
(Supplemental Figure 4A). The low number of under-expressed
genes in myeloid DC was significantly associated with adaptive
immune response regulation, including B cell proliferation and
immunoglobulin production (Supplemental Figure 4B). A
complete list of all DEGs per cell type is provided in the
Supplemental Table 4. Of note, principal component analysis of
RNA-seq data on neutrophils from COVID-19 patients, showed
partial segregation between those with favorable vs fatal outcome
(Figure 2B). Genes involved in antiviral activity (i.e., ISG15, MX1,
OAS1) and hyper-responsiveness of the immune system (i.e.,
TNFAIP8L2) were over-expressed in neutrophils from deceased







Age, median (range), years 60 (19–94) 59 (19–94) 75 (31–93)
Male, no. (%) 253 (49%) 240 (49%) 13 (57%)
Comorbidities, no (%)
Any 256 (50%) 236 (48%) 20 (87%)
Diabetes 58 (11%) 51 (10%) 7 (30%)
Hypercholesterolemia 52 (10%) 49 (10%) 3 (13%)
Hypertension 178 (35%) 163 (33%) 15 (65%)
Cardiovascular disease 56 (11%) 47 (10%) 9 (39%)
Solid tumor 15 (3%) 14 (3%) 1 (4%)
Hematological tumor 10 (2%) 7 (1%) 3 (13%)
Medical care, no. (%)
Non-hospitalized 118 (23%) 118 (24%) 0 (0%)
Hospitalized 395 (77%) 372 (76%) 23 (100%)
ICU 32 (6%) 19 (4%) 13 (57%)
Hospitalization, median (range), days 8 (1–50) 7 (1–50) 12 (1–32)
Follow-up, median (range), days 59 (1–129) 63 (1–129) 12 (1–62)May 2021 | Volume 12 | ArtiICU, intensive care unit.cle 659018
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of the T and B cell compartments to characterize antigen-dependent
differentiation of both cell types after SARS-CoV-2 infection (n=14).
Based on reference values from HDs (n=4), there were no
significant differences in the distribution of CD4 and CD8 T cell
naïve and memory subsets (Figure 2C). Similarly, the relative
distribution of 14/16 subsets within the B cell compartment was
similar between COVID-19 patients and HDs, except for the
percentage of immature/transitional and IgG3 memory B cells
(Figure 2D). However, there was a general trend for lower
percentages of multiple T and B cell subsets in PB of patients
with fatal (n=3) vs favorable (n=11) outcome. Statistical significance
in CD4 naïve and effector memory T cells, CD8 effector memory
and effector memory re-expressing CD45RA (TEMRA) T cells was
observed (Figure 2C), as well as IgG1 and IgA1 memory B cells
(Figure 2D). Taken together, the transcriptional andFrontiers in Immunology | www.frontiersin.org 6immunophenotypic data suggest an association between COVID-
19 severity and neutrophil activation as well as reduced levels of
adaptive immune subsets. These findings urged further analysis in
the larger cohort to unequivocally identify poor outcome associated
immune signatures.
Immunotype Identification and Association
With Patient Characteristics and
Clinical Outcome
Lymphopenia and neutrophilia have been associated with
increased risk of severe COVID-19 (2, 40, 41). Analysis of
absolute cell-type numbers among COVID-19 patients (n=513)
showed significant associations between lower lymphocyte
(P <0.001) and higher neutrophil (P=0.001) counts and fatal
COVID-19 (Supplemental Figure 5). However, there was
substantial heterogeneity in absolute leukocyte numbers amongA
C D
B
FIGURE 2 | Activation and differentiation of innate and adaptive immune cells after SARS-CoV-2 infection. (A) Number of differentially expressed genes (DEGs) in
myeloid dendritic cells (DC), basophils, plasmacytoid DC, classical monocytes, neutrophils and non-classical monocytes, isolated from peripheral blood (PB) samples of
COVID-19 patients (n=11) and age-matched healthy donors (HDs, n=4). The number of under- and over-expressed DEGs is depicted, and cell types were ordered
from the lowest to the highest number of DEGs. (B) Principal component analysis of RNA-seq data from neutrophils showing partial segregation between COVID-19
patients with favorable vs fatal outcome (left panel). DEGs in neutrophils from COVID-19 patients as shown in left panel (right panel). Percentage of antigen-dependent
differentiation of (C) T and (D) B cell subsets in the PB of 14 COVID-19 patients (11 alive and 3 deceased) and 4 age-matched HDs. Lines represent median values in
HDs; boxes correspond to minimum-to-maximum values in alive patients; and dots indicate individual deceased patients. *P <0.05; **P <0.01 between alive and
deceased COVID-19 patients. Hash symbol (#) indicates significant differences between HDs and COVID-19 patients (P <0.05). Statistical significance was calculated
using the Mann-Whitney test. CM, central memory; EM, effector memory; TEMRA, effector memory re-expressing CD45RA T cells.May 2021 | Volume 12 | Article 659018
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(17%) similar, and 11 (48%) higher leukocyte counts than the
median value in HDs. These data provide the rationale for using
cell-type percentages rather than absolute numbers for
subsequent analyses to provide more meaningful results.
Unsupervised clustering analysis according to the relative
distribution of the 17 immune cell-types identified three
distinct immunotypes among the 513 COVID-19 patients
(Figure 3A). The first branch of the analysis segregated a
single patient (0.2%) with diffuse large B-cell lymphoma and
therapy-related severe neutropenia who died from COVID-19
shortly after admission. The second branch separated a group of
74 (14.4%) patients (immunotype 1, dark gray) from the
remaining 438 (85.4%) patients. These patients were
subsequently divided at the third branch into two subgroupsFrontiers in Immunology | www.frontiersin.org 7containing 268 (52.3%; immunotype 2, gray) and 170 (33.1%;
immunotype 3, light gray) patients, respectively.
Patients with immunotype 1 were characterized by significantly
(P<0.0001) lower percentages of all immune cell-types except for
neutrophils and circulating PCs, which were increased, compared
to patients with immunotypes 2 and 3 (Supplemental Figure 6).
Immunotype 3 was characterized by an opposite distribution
pattern to immunotype 1, and immunotype 2 had intermediate
features between immunotypes 1 and 3. There were also
significant differences in age distributions, gender proportions,
rates of comorbidities, medical care required, median
hospitalization duration, and incidence of fatal COVID-19
between the three immunotypes (Table 2).
In accordance with these findings by immunotype,
percentages of neutrophils and circulating PCs wereA
B
FIGURE 3 | The immune landscape of patients with COVID-19 and its association with disease severity. (A) Unsupervised clustering of 513 patients with COVID-19
based on the relative distribution of 17 immune cell types in peripheral blood (PB) samples taken at presentation. For the columns to the left of the cell-percentage
data, moving from right to left, patient rows are color-coded according to age and gender; green and red marks indicate the patients with solid or hematological
tumors; dark gray marks indicate the presence of the comorbidities of hypertension, cardiovascular disease, hypercholesterolemia, and diabetes; light blue-to-green
marks indicate duration of hospitalization; and dark gray marks indicate patients requiring hospitalization (n=395), patients who needed intensive care unit (ICU)
admission (n=32), and patients who died (n=23). (B) Median percentages of the 17 immune cell-types in PB samples from patients with COVID-19 who were not
hospitalized (n=118) and those who required hospitalization (n=395), as well as the subsets of hospitalized patients who required ICU admission (n=32) and/or who
died from COVID-19 (n=23). *P <0.05; **P <0.01; ***P <0.001; ns, not significant. Statistical significance was evaluated using Mann–Whitney tests.May 2021 | Volume 12 | Article 659018
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types progressively lower when comparing non-hospitalized
patients versus hospitalized patients versus patients requiring
ICU admission versus patients who died (Figure 3B). Overall,
these results illustrate that the relative distribution of all immune
cell-types in PB at presentation is significantly associated with
specific pre-existing medical conditions and clinical outcome in
COVID-19 patients.
Clinical and Immune Prognostic Factors
for Survival: Multivariable Analysis
Optimal cutoffs for association with survival were determined for
percentages of each of the 17 immune cell-types based on ROC
curves; using these cutoffs, percentages of all immune cell-types
except circulating PCs predicted significantly different overall
survival (OS) (Supplemental Figure 7A). Similar results were
obtained using absolute cell numbers (Supplemental Figure 7B).
The increased risk of death was greatest in COVID-19 patients
with <1% versus ≥1% B cells (HR 17.1 [95% CI 7.0–41.6],
P <0.0001) and ≥76.22% versus <76.22% neutrophils (HR 14.9
[95% CI 5.9–37.7], P <0.0001). Clinical prognostic factors
associated with significantly poorer OS were age >70 years
(P=0.0002) and presence of any pre-existing medical
conditions (P=0.004) (data not shown).
On multivariable analysis, which included the 11 immune
cell-types with significant prognostic value and HR above 5,
plus age and presence of comorbidities, the relative
percentages of non-classical monocytes (HR 4.2 [95% CI
1.2–14.1], P=0.02) and B cells (HR 4.1 [95% CI 1.2–13.7],
P=0.02), and age >70 years (HR 4.0 [95% CI 1.6–10.2],Frontiers in Immunology | www.frontiersin.org 8P=0.003) were identified as independent prognostic factors
for OS (Supplemental Table 5). This immunoscore
comprising two immune cell-type risk-factors (<0.67% non-
classical monocytes; <1% B cells) was significantly predictive of
fatal COVID-19 based on ROC analysis (area under the curve
0.86 [95% CI 0.77–0.95], P <0.001; Supplemental Figure 8),
and stratified COVID-19 patients (n=513) aged either ≤70
years or >70 years into groups with significantly different OS
(Figure 4A). OS rates at 1 month were 99%, 97%, and 74% in
patients aged ≤70 years and 98%, 82.5%, and 15% in patients
aged >70 years who had 0, 1, or 2 risk-factors (P <0.0001),
respectively. The median OS for patients aged >70 years with
an immunoscore of two was 15 days. In the 355 patients of the
validation series, OS rates at 1 month were 100%, 97%, and
93% in patients aged ≤70 years and 96%, 95%, and 60% in
patients aged >70 years who had 0, 1, or 2 risk-factors,
respectively (Figure 4B). These results thus identify two
high-risk immune biomarkers that are independent of age
and pre-existing medical conditions.
Divergent Immune Response Trajectories
According to COVID-19 Outcome
Among the 167 COVID-19 patients with immune monitoring
during follow-up, there were significantly different changes in the
relative distribution of eight immune cell types from first to last
PB sample between patients who survived (n=158) versus those
who died (n=9). The latter showed reductions in percentages of
basophils and cytotoxic NK cells over time, together with static
percentages of double-negative, double-positive, CD8loCD56-,
and CD8-/loCD56+ T cells, and B cells. CD4+CD56- T cellsTABLE 2 | Demographics and clinical characteristics of COVID-19 patients (n=513) clustered according to their immune cell composition during SARS-CoV-2 infection.
Characteristics Unclustered patient
(N = 1; 0.2%)
Immunotype 1
(N = 74; 14.4%)
Immunotype 2
(N = 268; 52.3%)
Immunotype 3
(N = 170; 33.1%)
Significance
Age (years)
18–30 0 (0%) 1 (1%) 2 (0.7%) 16 (9%) b,c
31–55 1 (100%) 24 (32%) 76 (28%) 88 (52%) a,b
56–70 0 (0%) 22 (30%) 104 (39%) 32 (19%) b,c
>70 0 (0%) 27 (36%) 86 (32%) 34 (20%) a,c
Female, no. (%) 1 (100%) 31 (42%) 121 (45%) 107 (63%) b,c
Comorbidities, no. (%)
Any 1 (100%) 49 (66%) 145 (54%) 61 (36%) b,c
Diabetes 0 (0%) 13 (18%) 33 (12%) 12 (7%) ns
Hypercholesterolemia 0 (0%) 7 (9%) 30 (11%) 15 (9%) ns
Hypertension 0 (0%) 33 (45%) 109 (41%) 36 (21%) b,c
Cardiovascular disease 0 (0%) 14 (19%) 32 (12%) 10 (6%) b
Cancer 1 (100%) 7 (9%) 11 (4%) 6 (4%) ns
Medical care, no. (%)
Non-hospitalized 0 (0%) 4 (5%) 41 (15%) 73 (43%) a,b,c
Hospitalized 1 (100%) 70 (95%) 227 (85%) 97 (57%) a,b,c
ICU 1 (100%) 16 (22%) 9 (3%) 6 (4%) a,b
Hospitalization, median, days 26 10 7 8 a,c
Outcome, no. (%)
Died 1 (100%) 14 (19%) 7 (3%) 1 (0.6%) a,bMay 2021 | Volume 12 |ICU, intensive care unit.
a, significant difference between immunotypes 1 and 2.
b, significant difference between immunotypes 1 and 3.
c, significant difference between immunotypes 2 and 3.
ns, no significant differences among immunotypes.Article 659018
Martı́ n-Sá nchez et al. Immune Biomarkers for COVID-19 Severityincreased in patients who died, but not by as much as in patients
who survived (Figure 5A).
Longitudinal immune monitoring confirmed the divergent
immune trajectories between patients who survived or died, as
demonstrated in immune cell-type subsets including basophils,
CD8loCD56- T cells, and B cells (Figure 5B). These data on
immune profile at presentation and during follow-up demonstrate
that the level of B cells is of importance throughout the disease
course, whereas levels of specific innate and adaptive cell-type
subsets emerge as particularly relevant during hospitalization.DISCUSSION
Severe COVID-19 occurs more frequently in the elderly and in
those with comorbidities, leukocytosis, or lymphopenia (4, 42).
However, the relationships between age or clinical history and
immune dysfunction, as well as between disease severity and
immune response over time, remain poorly understood (1, 40,
43–45). Indeed, most of the initial studies were performed in
small series of patients and compared immune profiles in patients
with moderate or severe disease, or in those who recovered from
COVID-19. In the present study, we conducted a holistic and
unbiased analysis of the immune cell phenotype during SARS-Frontiers in Immunology | www.frontiersin.org 9CoV-2 infection in a large cohort of 513 patients who reflected the
wide age-range and medical history associated with COVID-19.
Our findings provide new insight into disease immunopathology
and identify key immune cell-types that are significantly
associated with OS, regardless of age and comorbidities.
Immune profiles have previously been compared between
COVID-19 patients and HDs in relatively small numbers of
subjects and without age-matching (11, 16, 21, 22). We showed
that the relative distribution of immune cell-types in PB is
affected by aging; these changes are characterized by an
expansion of neutrophils together with progressively reduced
levels of certain NK and T cell subsets. Our findings highlight
that comparisons of immune profiles between COVID-19
patients and HDs should be age-matched. Consistent with
previous studies (22), we observed higher percentages of
neutrophils as well as transcriptional activation of this plus
other myeloid subsets and DCs in COVID-19 patients
versus HDs. Conversely, we have not observed significant
downregulation of HLA-DR and other activation markers in
antigen-presenting cells in COVID-19 patients compared with
healthy adults. However, it should be noted that differences in
gene expression may emerge according to the anatomical
location of cells (46) and disease severity. Indeed, reduced
HLA-DR expression appears to be more pronounced inA
B
FIGURE 4 | Overall survival of patients with COVID-19 according to presence of two high-risk immune biomarkers identified in this study. (A) Patients had an
immunoscore of 0, 1, or 2 according to the absence or the presence of one or two risk factors, respectively: <0.67% non-classical monocytes and <1% B cells.
Among patients aged ≤70 years, 274, 80, and 12 had an immunoscore of 0, 1, or 2, respectively. Among patients aged >70 years, 107, 30, and 10 had an
immunoscore of 0, 1, or 2, respectively. (B) This immunoscore was further validated in an independent cohort of additional 355 patients with COVID-19, where 126,
91, and 15 patients aged ≤70 years had an immunoscore of 0, 1, or 2, respectively; whereas 55, 43, and 25 patients aged >70 years had an immunoscore of 0, 1,
or 2, respectively.May 2021 | Volume 12 | Article 659018
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the small number of patients analyzed herein with RNA-seq may
have limited the identification of deregulated antigen
presentation. Nevertheless, when considered together with
other studies showing elevated percentages of circulating PCs
(10, 11, 16, 21, 22), our data suggest that most COVID-19
patients display an expansion, activation, and differentiation of
multiple immune lineages during SARS-CoV-2 infection. These
findings are consistent with the neutralization of infection and
the asymptomatic or mild-to-moderate course of the disease
observed in 90% of cases (2, 4).
It remains unclear whether severe COVID-19, which is
observed in 5–10% of patients (2, 4), arises due to the
characteristics of the viral infection, patient demographics and
comorbidities, depth of immune response, or all three. In theFrontiers in Immunology | www.frontiersin.org 10present study, we reveal the presence of an immunotype in 14%
of patients that is characterized by an abnormally greater
expansion of neutrophils and circulating PCs, together with a
profound reduction of all other immune cell-types, and
associated with fatal outcome. Such changes could be
surrogates for both innate and adaptive over-reactivity to
SARS-CoV-2 infection, with heightened inflammation
potentially leading to the depletion of other effector cells (10).
These results confirm previous observations in smaller series that
showed increased neutrophil levels and reduced percentages of
multiple cell-types in patients with severe COVID-19 (10, 11, 16,
21, 22, 40), and unequivocally support a role for the host immune
response in determining the disease course.
Humoral immunity is critical for viral clearance and SARS-
CoV-2 elicits a robust B cell response, as evidenced by the rapidA
B
FIGURE 5 | Divergent immune response trajectories in patients with COVID-19 with longitudinal immune monitoring who had favorable (n=158) or fatal (n=9)
outcomes. (A) Absolute variations in percentages of immune cell-types from first to last PB sampling time point, according to outcome. *P <0.05; **P <0.01.
Statistical significance was evaluated using the Kruskal–Wallis test. (B) Longitudinal relative variations in percentages of immune cell-types from first through all
subsequent PB sampling time points, according to outcome.May 2021 | Volume 12 | Article 659018
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antibodies (51). Notwithstanding, most studies investigating
prognostic immune biomarkers for disease severity have
focused on total lymphocyte counts, the neutrophil-to-
lymphocyte ratio, or the neutrophil-to-CD8-T-cell ratio (1, 4,
20, 22, 43, 52). We found that, among all leukocyte subsets with
prognostic value, the percentage of B cells at presentation
showed the strongest association with OS; patients with <1% B
cells had a 17-fold greater risk of death versus those with ≥1% B
cells. To our knowledge, this is one of the first studies supporting
a prominent role for B cells in determining COVID-19 severity;
in this context, it might be hypothesized that plasma or
neutralizing antibodies from recovered patients (53–55) could
be used as immunoprophylaxis for patients with a low
percentage of B cells (51, 56). A percentage of neutrophils of
>76% was also strongly associated with inferior OS in our study.
An exacerbated inflammatory response associated with SARS-
CoV-2 infection could cause enhanced neutropoiesis and
increased neutrophil influx into the PB, in accordance with
recent observations of immature neutrophils in the PB of
patients with severe COVID-19 (16, 18, 24). Thus, a
predominant differentiation of hematopoietic stem cells into
the neutrophil lineage, reduced numbers of lymphoid
progenitors in elderly individuals’ bone marrow (57), as well as
elevated cytokine levels (58), could all contribute to the reduction
of virtually all lymphocyte subsets in the PB of patients with
severe COVID-19. Accordingly, we also showed for the first time
that the percentage of immature/transitional B cells (which
egress from the bone marrow into PB) was significantly lower
in COVID-19 patients vs HDs.
Additionally, we identified the percentage of non-classical
monocytes as an independent prognostic factor in the
multivariable analysis of OS. These data confirm recent
findings reported in 86 COVID-19 patients, in which a
decreased percentage of non-classical monocytes in PB
discriminated between moderate/severe and mild disease (24).
Lower levels of non-classical monocytes could be due to their
activation (as suggested by our RNA-seq data) and migration
from the PB into the inflamed lungs of critically ill patients;
accordingly, proinflammatory monocyte-derived macrophages
have been found to be abundant in the bronchoalveolar lavage
fluid from patients with severe COVID-19 (12). An important
aspect of our work is that, by combining these two independent
immune prognostic factors – percentages of B cells and non-
classical monocytes – we were able to develop an immunoscore
for risk-stratification that resulted in significant OS differences
among patients aged ≤70 years and those aged >70 years. These
results are clinically relevant because severe COVID-19 is
unusual in younger patients who do not have pre-existing
medical conditions, and presence of these high-risk immune
biomarkers could help physicians tailor their management of
these patients (4). Although our immunoscore did not reach
statistical significance in the prediction of OS in younger
patients of the validation cohort, this could be explained by
their better clinical management during the subsequent
outbreaks of COVID-19, which are not being as unpredictableFrontiers in Immunology | www.frontiersin.org 11as the first one. Nevertheless, we confirmed the usefulness of the
immunoscore in older patients in both series. Then, these
biomarkers might indicate the need for innovative treatment
strategies to overcome otherwise unsurmountable severe
COVID-19.
It has been speculated that critical illness caused by SARS-
CoV-2 infection can be a result of an immune response that is
too weak, leading to virus-induced pathology, or too strong,
leading to immune-induced pathology (21). We hypothesized
that longitudinal immune monitoring could shed light on these
differing immune response trajectories and help understand the
variability in clinical outcome that is not indicated solely by the
immune response at presentation. Our results build upon initial
observations suggesting that patients with severe COVID-19 had
progressive lymphopenia together with increasing neutrophil
counts in PB (1, 20, 43). Our data also reveal divergent
immune response trajectories with respective to other innate
and adaptive immune cell-types between COVID-19 patients
with favorable versus fatal outcomes.
Overall, considering our findings in HDs and in COVID-19
patients at presentation and during follow-up, it could be
hypothesized that an overly mature immune status could affect
a patient’s ability to produce an immediately effective humoral
response. Consequently, sustained inflammation due to
prolonged viral load would further compromise the feasibility
of neutralizing SARS-CoV-2 due to progressively lower levels of
NK and T cells. Thus, our study may contribute to a better
understanding of disease immunopathobiology and provides a
simple tool for risk-stratification of COVID-19 patients based on
immune status at presentation. This immunoscore is readily
applicable and may be widely utilized as, unfortunately, the
number of new confirmed cases of COVID-19 remains high
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F lowct : A Semi-Automated Workflow for Deconvolut ion of
Immunophenotypic Data and Objective Reporting on Large Datasets. Blood
(2019) 134(Supplement_1):4355–5. doi: 10.1182/blood-2019-122088
33. Van Gassen S, Callebaut B, Van Helden MJ, Lambrecht BN, Demeester P,
Dhaene T, et al. FlowSOM: Using Self-Organizing Maps for Visualization and
Interpretation of Cytometry Data. Cytometry A (2015) 87(7):636–45. doi:
10.1002/cyto.a.22625
34. Wilkerson MD, Hayes DN. ConsensusClusterPlus: A Class Discovery Tool
With Confidence Assessments and Item Tracking. Bioinformatics (2010) 26
(12):1572–3. doi: 10.1093/bioinformatics/btq170
35. Jaitin DA, Kenigsberg E, Keren-Shaul H, Elefant N, Paul F, Zaretsky I, et al.
Massively Parallel Single-Cell RNA-seq for Marker-Free Decomposition of Tissues
Into Cell Types. Science (2014) 343(6172):776–9. doi: 10.1126/science.1247651
36. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. Star:
Ultrafast Universal RNA-seq Aligner. Bioinformatics (2013) 29(1):15–21. doi:
10.1093/bioinformatics/bts635
37. Anders S, Pyl PT, Huber W. HTSeq-a Python Framework to Work With
High-Throughput Sequencing Data. Bioinformatics (2015) 31(2):166–9. doi:
10.1093/bioinformatics/btu638
38. Love MI, Huber W, Anders S. Moderated Estimation of Fold Change and
Dispersion for RNA-seq Data With DESeq2. Genome Biol (2014) 15(12):550.
doi: 10.1186/s13059-014-0550-8
39. Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: An R Package for
Comparing Biological Themes Among Gene Clusters. OMICS (2012) 16
(5):284–7. doi: 10.1089/omi.2011.0118
40. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and
Immunological Features of Severe and Moderate Coronavirus Disease 2019.
J Clin Invest (2020) 130(5):2620–9. doi: 10.1172/JCI137244
41. Henry BM, Cheruiyot I, Vikse J, Mutua V, Kipkorir V, Benoit J, et al.
Lymphopenia and Neutrophilia At Admission Predicts Severity and
Mortality in Patients With COVID-19: A Meta-Analysis. Acta Biomed
(2020) 91(3):1–16. doi: 10.23750/abm.v91i3.10217
42. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of
138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia
in Wuhan, China. JAMA (2020) 323(11):1061–9. doi: 10.1001/jama.2020.1585
43. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia
Predicts Disease Severity of COVID-19: A Descriptive and Predictive Study.
Signal Transduct Target Ther (2020) 5:61. doi: 10.1038/s41392-020-0159-1Frontiers in Immunology | www.frontiersin.org 1344. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional Exhaustion
of Antiviral Lymphocytes in COVID-19 Patients. Cell Mol Immunol (2020)
17:533–5. doi: 10.1038/s41423-020-0402-2
45. Shah V, Ko Ko T, Zuckerman M, Vidler J, Sharif S, Mehra V, et al. Poor
Outcome and Prolonged Persistence of SARS-CoV-2 RNA in COVID-19
Patients With Haematological Malignancies; King’s College Hospital
Experience. Br J Haematol (2020) 190(5):e279–e82. doi: 10.1111/bjh.16935
46. Daamen AR, Bachali P, Owen KA, Kingsmore KM, Hubbard EL, Labonte AC,
et al. Comprehensive Transcriptomic Analysis of COVID-19 Blood, Lung,
and Airway. Sci Rep (2021) 11(1):7052. doi: 10.1038/s41598-021-86002-x
47. Arunachalam PS, Wimmers F, Mok CKP, Perera RAPM, Scott M, Hagan T,
et al. Systems Biological Assessment of Immunity to Mild Versus Severe
COVID-19 Infection in Humans. Science (80- ) (2020) 369(6508):1210–20.
doi: 10.1126/science.abc6261
48. Zhang Q, Meng Y, Wang K, Zhang X, Chen W, Sheng J, et al. Inflammation
and Antiviral Immune Response Associated With Severe Progression of
COVID-19. Front Immunol (2021) 12:631226. doi: 10.3389/fimmu.2021.
631226
49. Zenarruzabeitia O, Astarloa-Pando G, Terrén I, Orrantia A, Pérez-Garay R,
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